STOCKHOLM, SE / ACCESS Newswire / January 29, 2025 / Vicore Pharma Holding (STO:VICO)Stockholm, January 29, 2025 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of ...

Numerous clinical studies have established that angiotensin II receptor blockers are effective as antihypertensive therapy and are well tolerated. Studies demonstrate that adding an angiotensin II ...

Angiotensin II (AT-II)-Receptor Antagonists are Reviewed. Research focused on blocking the renin- angiotensin system (RAS) led to the discovery of angiotensin-converting-enzyme (ACE) inhibitors ...

Several ASX-listed companies are making significant strides in their phase III clinical trials, the critical final stage ...

KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.

TOKYO, Jan. 30, 2025 /PRNewswire/ -- Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys Pharma") announced today that it has completed patient enrollment for its registrational Phase III ...

Renalys Pharma completes patient enrollment in registrational phase III trial of sparsentan for IgA nephropathy in Japan: Tokyo, Japan Friday, January 31, 2025, 18:00 Hrs [IST] Re ...

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH ...

R Squared Ltd bought a new position in Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & ...

Hantz Financial Services Inc. acquired a new position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) during the fourth quarter, according to the company in its most recent filing ...